Depending on patient characteristics, costs, potential for adverse effects, and patient preferences and priorities [38], options for the next secondary prevention therapy may include icosapent ethyl in patients with triglycerides ≥150 mg/dl [39], a sodium-glucose cotransporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 receptor (GLP-1) agonist in patients with diabetes or heart failure [40], or rivaroxaban in patients with coronary or peripheral artery disease at low bleeding risk [41, 42]. The gene discussed is GLP1R; the disease is heart failure.